Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan
A dynamic simulation models Alzheimer's diagnostic workflows in Japan.Blood biomarker (BBM) tests reduce diagnostic wait times for Alzheimer's in Japan.Implementing BBM tests improves access to Alzheimer's diagnostics.Study quantifies demand for diagnostic testing based on costs and accessibility.Testing costs impact the number of treatment-eligible Alzheimer's patients.
Authors
- Tomomi Takeshima (ORCID: https://orcid.org/0000-0002-0572-5145)
- Takuya Ataka (ORCID: https://orcid.org/0000-0001-9416-9867)
- Chizuru Kobayashi
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Akihiko Chida (ORCID: https://orcid.org/0009-0007-1894-4113)
- Kotaro Sasaki (ORCID: https://orcid.org/0000-0002-5604-2651)
- Noriyuki Kimura (ORCID: https://orcid.org/0000-0001-7137-7268)
- Yukinori Sakata
- Kosuke Iwasaki
- Etsuro Matsubara (ORCID: https://orcid.org/0009-0006-5150-1130)
- Mie Azuma
- Mami Tani
- Temmei Ito (ORCID: https://orcid.org/0000-0001-5834-594X)
Institutions
- Oita University (JP)
- Department of Health (IE)
- Eisai (Japan) (JP)
- The University of Tokyo (JP)
- Milliman (United States) (US)
- Yokohama City University (JP)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/trc2.70157
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen
- Eisai